Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients - Czech Center experience
| Autoři | |
|---|---|
| Rok publikování | 2023 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Haematologica |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | https://haematologica.org/article/view/haematol.2022.282263 |
| Doi | http://dx.doi.org/10.3324/haematol.2022.282263 |
| Klíčová slova | Gemtuzumab ozogamicin; midostaurin; acute myeloid leukemia |
| Přiložené soubory | |
| Popis | For more than four decades, conventional therapy for acute myeloid leukemia (AML) has been represented by cytarabine/anthracycline-containing regimens, followed by consolidation therapy, including allogeneic hematopoietic stem cell transplantation (allo-HSCT). In recent years, approach to the treatment of AML has significantly shifted toward the use of novel and effective, target-directed therapies, including anti-CD33 immunoconjugate, gemtuzumab ozogamicin (GO), and inhibitor of mutant FMS-like tyrosine kinase 3 (FLT3), midostaurin (MIDO). |
| Související projekty: |